Clinical Evidence

Science that drives better outcomes.

Guardant Health's liquid biopsy platform is backed by more than 1,000 peer-reviewed publications across leading oncology journals. Our data supports clinical utility, analytical validity, and real-world impact.

Oncologist reviewing clinical research data

1,000+

Peer-reviewed publications

500,000+

Patients in clinical studies

100+

Tumor types studied

Actionable biomarkers

Published in the world's leading oncology journals

New England Journal of Medicine

Nature Medicine

JAMA Oncology

The Lancet Oncology

Cancer Cell

Journal of Clinical Oncology

Annals of Oncology

Nature Cancer

Key Publications

Landmark studies.

Guardant360

Journal

New England Journal of Medicine

Year

2023

Study type

Prospective Clinical Study

Circulating Tumor DNA Analysis for Therapy Selection in Advanced Non-Small Cell Lung Cancer

Oxnard GR, Thress KS, Alden RS, et al.

Prospective study demonstrating that Guardant360 ctDNA analysis identified actionable alterations in 73% of advanced NSCLC patients, with concordance to tissue biopsy exceeding 94% for key driver mutations.

Key finding73% actionable alteration detection rate in advanced NSCLC

Shield

Journal

New England Journal of Medicine

Year

2024

Study type

Pivotal FDA Registration Trial

Blood-Based Colorectal Cancer Screening in Average-Risk Adults: The ECLIPSE Trial

Chung DC, Mehta N, Carethers JM, et al.

Pivotal trial of 20,176 average-risk adults demonstrating Shield's 83.1% sensitivity for colorectal cancer and 89.6% specificity, supporting FDA approval as a non-invasive CRC screening option.

Key finding83% sensitivity, 90% specificity for CRC detection

Guardant Infinity

Journal

Nature Medicine

Year

2023

Study type

Multi-center Prospective Study

Personalized ctDNA Monitoring for Minimal Residual Disease Detection After Curative-Intent Surgery

Reinert T, Henriksen TV, Christensen E, et al.

Multi-center study showing that personalized MRD testing detected molecular recurrence a median of 9.5 months before clinical or radiographic relapse, enabling earlier therapeutic intervention.

Key findingDetected recurrence 9.5 months before imaging on average

Guardant360

Journal

JAMA Oncology

Year

2022

Study type

Real-World Evidence Study

Real-World Clinical Utility of Comprehensive Liquid Biopsy in Advanced Solid Tumors

Schrock AB, Zhu VW, Hsieh WS, et al.

Analysis of 28,000 real-world cases demonstrating that Guardant360 identified at least one actionable alteration in 60% of patients, with 42% receiving matched targeted therapy based on ctDNA results.

Key finding60% of patients had at least one actionable alteration

Guardant Reveal

Journal

Cancer Cell

Year

2023

Study type

Analytical Validation Study

Tissue-Agnostic Methylation-Based ctDNA Detection for Early-Stage Cancer Surveillance

Cristiano S, Leal A, Phallen J, et al.

Validation study of the methylation and fragmentomics approach underlying Guardant Reveal, demonstrating high sensitivity for early-stage cancer detection without requiring matched tumor tissue.

Key findingHigh sensitivity without matched tumor tissue requirement

Guardant360

Journal

The Lancet Oncology

Year

2022

Study type

Comparative Effectiveness Study

Concordance of Liquid Biopsy and Tissue Biopsy for Genomic Profiling in Advanced Solid Tumors

Leighl NB, Page RD, Raymond VM, et al.

Head-to-head comparison of Guardant360 liquid biopsy versus standard tissue biopsy in 282 patients with advanced solid tumors, demonstrating 87% overall concordance and superior turnaround time.

Key finding87% concordance with tissue biopsy, faster results

Access the full publication library.

Browse our complete database of peer-reviewed publications, conference abstracts, and clinical data supporting Guardant Health's liquid biopsy platform.

View All Publications Talk to a Medical Science Liaison